Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris(University of Pittsburgh), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Makoto Tahara(National Cancer Center Hospital East), Francis P. Worden(Georgetown University), Mark Lynch(Fluidigm (United States)), Jérôme Fayette(Université Claude Bernard Lyon 1), Tamara Rordorf(Institut Gustave Roussy), Naomi Kiyota(Kobe University Hospital), Nabil F. Saba(Emory University), Lisa Licitra(University of Milan), Lara Carmen Iglesias Docampo(Institut Gustave Roussy), Everett E. Vokes(University of Chicago), A. Dimitrios Colevas(Cancer Institute (WIA)), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Vijayvel Jayaprakash(Roswell Park Comprehensive Cancer Center), Robert I. Haddad(Georgetown University), Li Li(Yantai University), Stefan Kasper(Essen University Hospital), Caroline Even(Institut Gustave Roussy), J. Guigay(Centre Antoine Lacassagne)
Cited by 802
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k